172 related articles for article (PubMed ID: 12970288)
1. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.
Viereck V; Gründker C; Blaschke S; Niederkleine B; Siggelkow H; Frosch KH; Raddatz D; Emons G; Hofbauer LC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4206-13. PubMed ID: 12970288
[TBL] [Abstract][Full Text] [Related]
2. Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts.
Viereck V; Gründker C; Friess SC; Frosch KH; Raddatz D; Schoppet M; Nisslein T; Emons G; Hofbauer LC
J Bone Miner Res; 2005 Nov; 20(11):2036-43. PubMed ID: 16234977
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.
Viereck V; Emons G; Lauck V; Frosch KH; Blaschke S; Gründker C; Hofbauer LC
Biochem Biophys Res Commun; 2002 Mar; 291(3):680-6. PubMed ID: 11855844
[TBL] [Abstract][Full Text] [Related]
4. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts.
Viereck V; Gründker C; Blaschke S; Siggelkow H; Emons G; Hofbauer LC
J Cell Biochem; 2002; 84(4):725-35. PubMed ID: 11835398
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts.
Viereck V; Gründker C; Blaschke S; Frosch KH; Schoppet M; Emons G; Hofbauer LC
J Cell Biochem; 2005 Dec; 96(6):1244-53. PubMed ID: 16152630
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
Hofbauer LC; Gori F; Riggs BL; Lacey DL; Dunstan CR; Spelsberg TC; Khosla S
Endocrinology; 1999 Oct; 140(10):4382-9. PubMed ID: 10499489
[TBL] [Abstract][Full Text] [Related]
8. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.
Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Spelsberg TC; Riggs BL
Endocrinology; 1999 Sep; 140(9):4367-70. PubMed ID: 10465311
[TBL] [Abstract][Full Text] [Related]
9. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.
Bord S; Ireland DC; Beavan SR; Compston JE
Bone; 2003 Feb; 32(2):136-41. PubMed ID: 12633785
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
11. A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets.
De Wilde A; Lieberherr M; Colin C; Pointillart A
J Cell Physiol; 2004 Aug; 200(2):253-62. PubMed ID: 15174095
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women.
Messalli EM; Mainini G; Scaffa C; Cafiero A; Salzillo PL; Ragucci A; Cobellis L
Maturitas; 2007 Jan; 56(1):38-44. PubMed ID: 16787719
[TBL] [Abstract][Full Text] [Related]
13. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey EL; Williams JH; Davie MW; Marshall MJ
Bone; 2006 May; 38(5):652-61. PubMed ID: 16298558
[TBL] [Abstract][Full Text] [Related]
14. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
18. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
Wada N; Maeda H; Yoshimine Y; Akamine A
Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
[TBL] [Abstract][Full Text] [Related]
19. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells.
Wang Y; Li LZ; Zhang YL; Zhu YQ; Wu J; Sun WJ
Mol Cell Endocrinol; 2011 Apr; 337(1-2):43-51. PubMed ID: 21291955
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
